Edesa Biotech (EDSA) vs eXoZymes (EXOZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed eXoZymes (EXOZ) over the past year, gaining 34.6% versus a loss of 59.7%. Edesa Biotech is the larger company by market cap ($49.5 million vs $49.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | EXOZ |
|---|---|---|
| Share price | $3.66 | $5.27 |
| Market cap | $49.45M | $49.04M |
| 1-day change | -5.79% | -4.87% |
| YTD return | +157.75% | -51.65% |
| 1-year return | +34.56% | -59.68% |
| 5-year return | -93.31% | — |
| EPS (TTM) | $-1.72 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $18.40 |
| 52-week low | $0.72 | $4.35 |
| Distance from 52-week high | -81.99% | -71.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +346.17% | — |
| Average volume | 61.89K | 6.97K |
| Shares outstanding | 13.51M | 9.30M |
| Employees | 17 | 32 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed EXOZ by 94.2 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Healthcare · Biotechnology · 32 employees
EDSA vs EXOZ FAQ
Which is bigger, Edesa Biotech or eXoZymes?
Edesa Biotech (EDSA) is larger, with a market capitalization of $49.45M compared with $49.04M for eXoZymes (EXOZ).
Which stock has performed better over the past year, EDSA or EXOZ?
EDSA returned +34.56% over the past 12 months, compared with -59.68% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and eXoZymes in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.